Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.47 |
| ▸ | TTK | P33981 | 4/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17467246 | 0.90 | EGFR (0.49) | EGFRPTK2TTKIGF1RCCNA2 | |
| SCHEMBL17467230 | 0.89 | EGFR (0.46) | EGFRPTK2TTKIGF1R | |
| SCHEMBL17467233 | 0.87 | EGFR (0.67) | EGFRIGF1R | |
| SCHEMBL17467059 | 0.85 | EGFR (0.49) | EGFRPTK2TTKIGF1RCCNA2 | |
| SCHEMBL17466920 | 0.80 | TTK (0.39) | EGFRPTK2TTKCCNA2CDK2 | |
| SCHEMBL17467223 | 0.80 | EGFR (0.48) | EGFRPTK2TTKIGF1R | |
| SCHEMBL17466973 | 0.79 | EGFR (0.64) | EGFR | |
| SCHEMBL17467244 | 0.78 | EGFR (0.68) | EGFRIGF1R | |
| SCHEMBL17467052 | 0.77 | EGFR (0.48) | EGFRPTK2TTKIGF1RCCNA2 | |
| SCHEMBL17467215 | 0.75 | EGFR (0.73) | EGFRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890168-B2 | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2018-02-13 | — | — | US | disclosed |
| US-9890168-B2 | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2018-02-13 | — | — | US | disclosed |
| US-20170233395-A1 | 2,4-DISUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND MEDICINAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-08-17 | — | — | US | disclosed |
| US-20170233395-A1 | 2,4-DISUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND MEDICINAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-08-17 | — | — | US | disclosed |
| EP-3173412-A1 | 2,4-DISUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND MEDICINAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016011979-A1 | 2,4-DISUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND MEDICINAL USE THEREOF | 上海海雁医药科技有限公司 | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233395-A1 | 2,4-DISUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND MEDICINAL USE THEREOF | TYMP, TPMT, TYMS | EGFR 4341/4885PTK2 4811/4885TTK 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.